Argenx Se (ARGX) Gross Profit Growth (1y) (2023 - 2026)
Powered by 
Analysis
Argenx Se (ARGX) Gross Profit Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 17.43% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 11.52% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 11.24% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 15.59% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 63.51% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 126.09% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 57.16% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -3.99% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 351.57% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -95.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 63.51% |
| Mar 31, 2026 | 66.01% |
| Dec 31, 2025 | 71.01% |
| Sep 30, 2025 | 97.99% |
| Jun 30, 2025 | 97.02% |
| Mar 31, 2025 | 99.66% |
| Dec 31, 2024 | 98.38% |
| Sep 30, 2024 | 75.34% |
| Jun 30, 2024 | 73.37% |
| Mar 31, 2024 | 77.83% |
| Dec 31, 2023 | 108.50% |
| Sep 30, 2023 | 142.10% |
| Jun 30, 2023 | 251.30% |
| Mar 31, 2023 | 908.98% |